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AbstrACt
Objective We report on: (1) the proportion of patients with 
known atrial fibrillation (AF); and (2) demographic, clinical 
or radiological differences between patients with known AF 
(and not treated) and patients with newly diagnosed AF, in 
a cohort of patients who presented with ischaemic stroke 
or transient ischaemic attack (TIA) not previously treated 
with anticoagulation.
Design We reviewed cross-sectional baseline 
demographic and clinical data from a prospective 
observational cohort study, (CROMIS-2).
setting Patients were recruited from 79 hospital 
stroke centres throughout the UK and one centre in the 
Netherlands.
Participants Patients were eligible if they were adults 
who presented with ischaemic stroke or TIA and AF and 
had not been previously treated with oral anticoagulation.
Main outcome measures Proportion of patients with 
known AF before index ischaemic stroke or TIA from a 
cohort of patients who have not been previously treated 
with oral anticoagulation. Secondary analysis includes the 
comparison of CHA
2DS2-VASc and HAS-BLED scores and 
other demographics and risk factors between those with 
newly diagnosed AF and those with previously known AF.
results Of 1470 patients included in the analysis (mean 
age 76 years (SD 10)), 622 (42%) were female; 999 (68%) 
patients had newly diagnosed AF and 471 (32%) patients 
had known AF. Of the 471 patients with known AF, 68% 
had a strong indication for anticoagulation and 89% 
should have been considered for anticoagulation based 
upon CHA
2DS2-VASc score. Patients with known AF were 
more likely to have a prior history of dementia (4% vs 2%, 
p=0.02) and had higher HAS-BLED scores (median 3 vs 2). 
CHA
2DS2-VASc, other risk factors and demographics were 
similar.
Conclusions About 1/3 of patients who present with 
stroke and have AF who have not been treated with 
oral anticoagulation have previously known AF. Of these 
patients, at least 68% were not adequately treated with 
oral anticoagulation.
trial registration number NCT02513316.
IntrODuCtIOn
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia and is a major cause of 
ischaemic stroke.1 Current clinical guide-
lines recommend anticoagulation to reduce 
ischaemic complications in AF whereas anti-
platelets are less effective and therefore no 
longer recommended.2 Despite a wealth of 
evidence supporting the use of anticoagu-
lation for primary prevention of ischaemic 
stroke in people with AF—and the creation 
of ischaemic (CHA2DS2-VASc) and bleeding 
(HAS-BLED) risk scores to aid clinicians3 4—
anticoagulant underuse is well documented, 
strengths and limitations of this study
 ► CROMIS-2 atrial fibrillation (AF) was a prospective 
multicentre observational study with a richly phe-
notyped patient population, allowing us to explore 
multiple demographic and clinical variables.
 ► We recruited from multiple centres and the re-
sults therefore reflect a range of clinical practices 
throughout the UK.
 ► The sample size is large and to our knowledge, is 
the first and only study to look at structural imaging 
markers of small vessel disease when investigating 
this clinical question.
 ► CROMIS-2 did not collect information on patient 
preference not to be anticoagulated, the burden or 
paroxysms in those with paroxysmal AF, or the rea-
son the general  practitioner/cardiologist/physician 
decided the patient was not to be anticoagulated, 
such as assessment of frailty.
 ► Our sample included patients who underwent MRI 
and provided informed personal or consultee con-
sent, and excluded patients previously treated with 
anticoagulation so might not represent the complete 
population of patients with ischaemic stroke and AF.
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with little recent improvement over the last decade.5 6 
Moreover, the reasons for non-treatment with oral anti-
coagulation in those at risk of ischaemic stroke remain 
uncertain.
Using the dataset of a multicentre, prospective obser-
vational inception cohort study of patients with AF and 
ischaemic stroke without oral anticoagulants before their 
index stroke, we sought to determine: (1) the proportion 
of patients with known AF compared with patients newly 
diagnosed with AF and (2) report on any demographic, 
clinical or radiological differences between patients with 
known AF (and not treated) and patients with newly diag-
nosed AF from a cohort of patient not previously treated 
with anticoagulation.
MethODs
This cross-sectional analysis is from the CROMIS-2 
AF study,7 a prospective multicentre inception cohort 
study recruiting from 79 hospital stroke centres in the 
UK and one centre in the Netherlands between August 
2011 and July 2015. In CROMIS-2 AF, patients were 
eligible if they were adults (aged over 18 years) presenting 
with ischaemic stroke or TIA and had AF (known or new 
onset) for which anticoagulation was to be commenced. 
Patients were excluded from CROMIS-2 AF if they had 
previously been treated with anticoagulation.
Patient and public involvement
The CROMIS-2 protocol was reviewed by a stroke patient 
panel. The results of CROMIS-2 have been presented at 
major conferences and are open access.
Data collection of baseline characteristics, ChA2Ds2-VAsc and 
hAs-bLeD score
The following baseline characteristics were prospectively 
collected by trained stroke research practitioners: age, 
sex, baseline, stroke severity using the National Institutes 
of Health Stroke Scale (NIHSS) at index event, prior use 
of antiplatelet agents before the index stroke, presence 
(or absence) of the following risk factors: AF diagnosed 
before stroke or TIA, hypertension, diabetes mellitus, 
hyperlipidaemia, history of ischaemic stroke (other than 
index stroke), history of intracerebral haemorrhage, 
history of cognitive impairment or dementia, current 
smoker and alcohol use(defined as ≥8 units per week)
We calculated composite CHA2DS2-VASc
8 and 
HAS-BLED4 scores before the index stroke for each 
patient. When calculating CHA2DS2-VASc and HAS-BLED 
score, we defined hypertension if the patient had a history 
of hypertension or was on antihypertensive medication. 
We did not included time in therapeutic range when 
calculating HAS-BLED as no patients were on previous 
anticoagulation.
Imaging analysis
A PhD (clinical neurology) student (DW) trained in 
rating structural markers of cerebral small vessel disease 
rated cerebral microbleeds, white matter hyperinten-
sities and cortical superficial siderosis using validated 
or widely accepted scoring systems in accordance with 
STRIVE (Standards for reporting vascular changes on 
neuroimaging) consensus guidelines.9–11 We consid-
ered white matter hyperintensities severe if they were 
confluent (score 2 or above in either the periventricular 
or deep white matter)
Outcome measures and statistical analysis
The primary outcome measure was the proportion of 
patients with AF known before the index stroke. In a 
secondary analysis, we compared (1) CHA2DS2-VASc 
scores (using two thresholds: CHA2DS2-VASc score 
reaching evidence for recommended oral anticoagula-
tion (class 1, level A evidence) and CHA2DS2-VASc score 
reaching evidence for consideration of oral anticoagula-
tion (class 2a level b evidence) (2) HAS-BLED scores and 
(3) demographic and baseline characteristics between 
patients with known AF before study entry and those with 
newly diagnosed AF at study entry.
We performed group comparison using the χ2 test for 
categorical variables and the Mann-Whitney U-test for 
continuous variables. All tests were two-tailed, and statis-
tical significance was determined at α-level of 0.05. We 
performed statistical analyses using STATA V.13.
resuLts
Of the 1490 patients, 1470 (99%) enrolled in CROMIS-2 
had information on whether their AF was newly diagnosed 
at study entry or previously known. The mean age of the 
cohort was 76 years (SD 10) and 622 (42%) were female. 
Median NIHSS (available in 928 patients) at stroke onset 
was 4 (IQR 2 to 9). 1234 patients (84%) presented with a 
stroke, 236 (16%) with a TIA.
Of the 1470 patients, 999 (68%) patients had newly 
diagnosed AF at study entry and 471 (32%) had known 
AF prior to the occurrence of ischaemic stroke or TIA. 
CHA2DS2-VASc scores (median 3 for both, IQR 2–4) 
(figure 1) did not differ significantly between both groups. 
In line with current European guidelines, of the patients 
with known AF prior to their qualifying stroke 304/447 
(68%) had a strong indication for anticoagulation (male 
Figure 1 Distribution of HAS-BLED and CHA2DS2-VASc 
scores between patients with known AF versus those with 
newly diagnosed AF. AF, atrial fibrillation. 
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patient with a CHA2DS2-VASc score of two or more or 
female patient with a CHA2DS2-VASc score of three or 
more) and 396/447 (89%) ought to have been considered 
for anticoagulation (male patients with a CHA2DS2-VASc 
score of one or more, female patients with a CHA2DS2-
VASc score of 2 or more).2 Patients with known AF before 
their ischaemic stroke or TIA had higher HAS-BLED 
scores compared with those with newly diagnosed with AF 
(median 3 (IQR 2–3) vs 2, (IQR 2–3) p=0.010) (figure 1). 
Significantly more patients with known AF were on anti-
platelet agents before the index stroke compared with 
patients with newly diagnosed AF (73% vs 43%, p<0.001). 
Patients with known AF were more likely to have a prior 
history of dementia or cognitive impairment (4% vs 2%, 
p=0.010), more likely to have hypertension (69% vs 61%, 
p=0.002) and hyperlipdaemia (49% vs 42%, p=0.019) and 
more likely to have ischaemic heart disease (22% vs 14%, 
p<0.001). Other variables in patients with known AF and 
those with newly diagnosed AF did not differ significantly 
including the presence of small vessel disease structural 
imaging markers. (table 1)
Given the significant difference in HAS-BLED scores 
between patients with known AF and those with newly 
diagnosed AF, we evaluated this further by exploring 
the individual components of the score. This revealed 
a significant difference in medications predisposing to 
bleeding between the two groups (73% vs 46%, p<0.001). 
Of the medications predisposing to bleeding, 95% were 
taking antiplatelets and 5% were taking non-steroidal 
anti-inflammatory drugs. The probable indications for 
antiplatelets were also different between the groups; the 
known AF patients had a significantly higher prevalence 
of ischaemic heart disease 22% vs 14%.
DIsCussIOn
In this cohort of patients with ischaemic stroke or TIA 
and AF, we found that 396/447 (89%) of patients with 









Age, (SD) 76 (10) 75 (10) 77 (11) 0.04
Age (SD) in those with only one risk factor other than sex 68 (8) 67 (8) 66 (7) 0.501
Sex, female, n (%) 622 (42) 404 (40) 218 (46) 0.034
Known hypertension,n (%) 915 (63) 594/983 (60) 321/465 (69) 0.002
Known diabetes mellitus, n (%) 243/1469 (17) 164/998 (16) 79 (17) 0.87
Known hyperlipidaemia, n (%) 649/1449 (45) 421/986 (43) 228/463 (49) 0.019
Current smoker, n(%) 165/1425 (12) 114/968 (12) 51/461 (11) 0.674
Excessive alcohol, n(%) 110/1365 (8) 79/929 (9) 31/436 (7) 0.378
Prestroke mRS, median (IQR) 0 (0 to 0) 0 (0 to 0) 0 (0 to 1) 0.002
Dependant living n (%) 97/1435 (7) 58/974 (6) 39/461 (8) 0.076
Previous ischaemic stroke n(%) 141/1445 (10) 94/977 (10) 47/468 (10) 0.801
Previous ICH n(%) 8/1450 (0.5) 5/981 (0.5) 3/469 (0.6) 0.719
Ischaemic heart disease n(%) 241 (16) 137 (14) 104 (22) <0.001
Known dementia/cognitive impairment n(%) 37/1463 (3) 18/996 (2) 19/467 (4) 0.010
Known peripheral vascular disease n (%) 31/1445 (2) 19/990 (2) 12/464 (3) 0.412
Antiplatelets on admission, n (%) 765/1455 (53) 423/986 (43) 342/469 (73) <0.001
Cerebral microbleeds, presence, n (%) 308 (21) 207 (21) 101 (21) 0.751
Confluent white matter hyperintensities, presence, n (%) 428 (29) 281 (28) 147 (31) 0.225
Cortical superficial siderosis, presence, n (%) 5 (0.3) 5 (0.5) 0 (0.0) 0.183
Prestroke CHA2DS2-VASc, median, (IQR)
(available in 1374 patients)
3 (2 to 4) 3 (2 to 4) 3 (2 to 4) 0.001
CHA2DS2-VASc score≥1 n (%) 1306/1374 (95) 877/927 (95) 429/447(96) 0.274
CHA2DS2-VASc score reaching evidence for recommended oral 
anticoagulation (class 1a evidence), n (%)
895/1374 (65) 591/927 (64) 304/447 (68) 0.121
CHA2DS2-VASc score reaching evidence for consideration of oral 
anticoagulation (class 2b evidence) n (%)
1182/1374 (86) 786/927 (85) 396/447 (89) 0.057
Prestroke HAS-BLED median (IQR) (available in 1280 patients) 3 (2 to 3) 2 (2 to 3) 3 (2 to 3) 0.010
AF, atrial fibrillation; ICH, intracerebral haemorrhage; mRS, modified Rankin Scale.
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known AF had a CHA2DS2-VASc score indicating antico-
agulation should be considered yet were not anticoagu-
lated at the time of their qualifying stroke representing a 
potential missed opportunity to prevent their ischaemic 
stroke or TIA.
In our cohort of patients with stroke and known AF, 
68% were at high risk of ischaemic stroke with a strong 
indication for anticoagulation.2 Although not a true 
denominator group (which would require patients from 
the same population with known AF who did not have 
strokes), the patients who presented with stroke and 
newly diagnosed AF do serve as a comparator to generate 
hypotheses regarding why patients with known AF are 
not being appropriately anticoagulated. In comparison 
with the patients with newly diagnosed AF, patients with 
known AF had a higher prevalence of cognitive impair-
ment or dementia, higher prevalence of hypertension 
and hyperlipidaemia and higher HAS-BLED scores. The 
HAS-BLED scores were higher, mainly due to the use of 
antiplatelet agents before their index stroke. There was 
no difference between structural imaging markers of 
the cerebral small vessel diseases that cause over 80% of 
spontaneous (nontraumatic) intracerebral haemorrhage. 
We found no difference in the neuroimaging features 
associated with so-called ‘bleeding prone arteriopathies’ 
(namely cerebral microbleeds and cortical superficial 
siderosis, features of cerebral amyloid angiopathy) on 
brain imaging between those with known AF compared 
with those with newly diagnosed AF.
Our finding that a large proportion of patients who 
present with stroke and have AF and have not been 
previously treated with oral anticoagulation, have previ-
ously known AF is consistent with previous studies, 
although most of these were retrospective. For example, 
a large retrospective Finnish registry study involving 3404 
patients with AF investigating ischaemic stroke events 
showed that only 55% of patients at high risk of ischaemic 
stroke (CHADS2 ≥2) were anticoagulated.
5 The most 
common reason for withholding anticoagulation in this 
cohort were infrequent paroxysms of AF (14%), previous 
bleeding (13%) and patient choice (9%), although no 
clear reason was documented in the majority of cases 
(35%). The percentage of patients with a CHADS2 ≥2 who 
were anticoagulated increased over the study period 
between 2003 and 2012 (from 49% to 65%, p<0.001). 
A large Swedish retrospective cross-sectional cohort of 
patients with AF spanning 2004 to 2010 found that only 
48% of patients with AF were treated with oral antico-
agulants, and of those that were not, 75% did not have 
a documented reason for withholding.6 Similarly, data 
from a New Zealand registry from 2010 to 2014 including 
10 406 patients with AF and a CHA2DS2-VASc≥2 found 
that only 6298 (61%) were using anticoagulation.12 Data 
from a large North American cohort of just under 95 000 
patients from the ‘get with the guidelines’ programme 
showed that only 16% of patients with known AF were 
receiving anticoagulation.13 By contrast with these 
studies, a prospective registry14 of consecutive patients 
from European centres reported that patients with known 
AF and CHA2DS2-VASc≥2 had a higher rate of anticoagu-
lant use (86%; 5600 of 7493 patients) than we observed. 
However, patients were recruited from hospital-based 
centres, so might not reflect practice in primary care. Of 
note, CROMIS-2 AF has the advantage of being a prospec-
tive inception cohort with excellent phenotyping, so does 
not rely on discharge and general practice codes to iden-
tify diagnosis and risk factors, which can be inaccurate. 
Of note, most of our patients (68%) had newly diagnosed 
AF at the time of their qualifying stroke. A proportion of 
these patients might have had undiagnosed AF for some 
time before the stroke. With accessible technology (such 
as heart monitors in watches) becoming more prevalent, 
it is possible that the proportion of patients with known 
AF will increase, presenting a further opportunity to 
prevent ischaemic stroke in the future.
Although our study highlights the ongoing underuse 
of anticoagulants in patients with known AF, we were 
unable to draw firm conclusions for several reasons: 
most importantly, we excluded patients who were on or 
previously exposed to anticoagulation, thus we do not 
know how many patients had ischaemic strokes despite 
anticoagulation. While we found a higher prevalence of 
dementia and cognitive impairment in the patients with 
known AF, this only accounted for 19 patients (4%). As 
96% of patients in CROMIS-2 AF were subsequently anti-
coagulated,7 it seems unlikely that a strong and persistent 
contraindication to anticoagulation would explain our 
results. Although we acknowledge that the strength of 
the indication for anticoagulation could change after 
having a TIA or stroke, we did not observe a difference 
in previous ischaemic or haemorrhagic stroke when 
comparing those with known and new AF. Secular changes 
in guidelines are also unlikely to have influenced results 
as our recruitment started in 2012 and finished in 2015. 
The European Society of Cardiology guidelines on AF 
were updated in 2012 and then not again until 2016, so 
all treatment of patients within the CROMIS-2 AF cohort 
should have followed the 2012 guidance (which recom-
mends anticoagulation for CHA2DS2-VASc≥1). Ambi-
guity regarding ischaemic stroke risk in patients with low 
CHA2DS2VASc scores might be another potential reason 
for the low anticoagulation rates in our cohort. A recent 
study revealed a wide variation in reported rates of stroke 
across cohorts, especially those with low CHA2DS2-VASc 
scores (0–1),15 where the low rate of subsequent stroke 
does not indicate a clear expected net benefit with antico-
agulation. This is reflected in the 2016 European Society 
of Cardiology guidelines which recommend anticoagula-
tion for males with a CHA2DS2-VASc≥1 and females with a 
CHA2DS2-VASc≥2. The higher HAS-BLED score in those 
with known AF was largely being driven by a higher use 
of antiplatelets. Nevertheless, we do not know the defi-
nite indication for antiplatelets in this patient group and 
whether antiplatelets were being used as an oral antico-
agulant replacement, although the higher percentage 
of ischaemic heart disease in the known AF group may 
 o
n




pen: first published as 10.1136/bmjopen-2018-028387 on 24 July 2019. Downloaded from 
5Wilson D, et al. BMJ Open 2019;9:e028387. doi:10.1136/bmjopen-2018-028387
Open access
partially explain this difference; a clear indication for 
antiplatelet agents may dissuade the use of anticoagu-
lants, in particular, if dual antiplatelet agents are used, 
but this does not fully account for the cohort. A higher 
HAS-BLED score should not exclude anticoagulation per 
se; HAS-BLED scores≥3 should identify patients at higher 
risk of bleeding, leading to closer monitoring and reduc-
tion in modifiable risk factors,2 rather than a reason to not 
anticoagulate. Indeed, studies have shown that patients 
with higher HAS-BLED score benefit the most from anti-
coagulation.16 17 Furthermore, the higher predisposition 
to major bleeding should not discourage clinicians from 
starting anticogulants as the bleeding risk on aspirin is 
comparable to the bleeding risk on warfarin.18
Our study has strengths; CROMIS-2 AF was a prospec-
tive multicentre observational study with a richly pheno-
typed patient population, allowing us to explore multiple 
demographic and clinical variables. It recruited from 
multiple centres and the results therefore reflect a range 
of clinical practice. The sample size is large and to our 
knowledge, is the first and only study to look at structural 
imaging markers of small vessel disease when exploring 
this clinial question. Since intention to anticoagulate was 
an inclusion criterion we were able to investigate a cohort 
without clear contraindications to treatment. The main 
weakness of our study with regard to the current paper is 
that CROMIS-2 was not designed to answer this research 
question; rather, this post-hoc analysis was designed to 
determine the extent of ongoing underuse of anticoagula-
tion in primary stroke prevention in patients with AF and 
generate hypotheses to explain the findings. CROMIS-2 
did not collect information on: patient preference not 
to be anticoagulated; the burden or paroxysms in those 
with paroxysmal AF; reasons for antiplatelet therapy; or 
reasons that the treating physician or GP decided against 
anticoagulation, for example, the assessment of frailty. 
We also acknowledge some strokes may have not been 
related to AF, although expect this to have been similar 
across the two groups.
Nevertheless, our findings show patients with AF who 
are at risk of ischaemic stroke are not being treated 
adequately, with little progress has been made over the 
last quarter-century.19 Further improvements in educa-
tion to both primary and secondary care physicians as 
well as patients are required. Bleeding risk scores also 
need to be interpreted as they were designed: to identify 
patients for closer monitoring and treatment of modifi-
able risk factors, and not as a tool to avoid starting antico-
agulation.20 Healthcare policies should focus on closing 
this persistent translational gap.
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